Page last updated: 2024-11-05

1,6-hexamethylene diisocyanate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

hexamethylene diisocyanate : A diisocyanate compound with the two isocyanates linked by a hexane-1,6-diyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID13192
CHEMBL ID1896533
CHEBI ID53578
SCHEMBL ID15038
MeSH IDM0064409

Synonyms (85)

Synonym
hexamethylendiisokyanat
ec 212-485-8
0i70a3i1uf ,
ccris 8431
hexamethylene diisocyanate [un2281] [poison]
unii-0i70a3i1uf
STL301890
1,6-diisocyanato-hexane
desmodur h
un2281
hexamethylene diisocyanate, 1,6-
isocyanic acid, diester with 1,6-hexanediol
hexamethylene-1,6-diisocyanate
hexamethylene-1,6-diisocyanate [diisocyanates]
hsdb 6134
nsc 11687
brn 0956709
ai3-28285
1,6-hexanediol diisocyanate
szesciometylenodwuizocyjanian [polish]
metyleno-bis-fenyloizocyjanian [polish]
einecs 212-485-8
hexamethylendiisokyanat [czech]
isocyanic acid,6-hexanediol
szesciometylenodwuizocyjanian
tl 78
wln: ocn6nco
hexane,6-diisocyanato-
hexane 1,6-diisocyanate
1,6-hexamethylene diisocyanate
nsc-11687
isocyanic acid, hexamethylene ester
hmdi
nsc11687
1,6-diisocyanatohexane
822-06-0
hexamethylene diisocyanate
1,6-hexylene diisocyanate
hexamethylene 1,6-diisocyanate
metyleno-bis-fenyloizocyjanian
1,6-hexane diisocyanate
hexane, 1,6-diisocyanato-
inchi=1/c8h12n2o2/c11-7-9-5-3-1-2-4-6-10-8-12/h1-6h
hexane,1,6-diisocyanate
HDI ,
1,6-diisocyanatohexane, 98%
NCGC00164175-01
hexamethylene diisocyanate, puriss., >=99.0% (gc)
CHEBI:53578 ,
H0324
AKOS000120355
A840272
NCGC00164175-03
NCGC00164175-02
tox21_300161
cas-822-06-0
dtxsid4024143 ,
NCGC00259755-01
dtxcid004143
NCGC00254122-01
tox21_202206
FT-0627021
s 90
hexamethylene-1,6-diisocyanate (diisocyanates)
hexamethylene diisocyanate [hsdb]
1,6-hexamethylene di-isocyanate
1,6-hexamethylene diisocyanate [inci]
s-90
hexamethylenediisocyanate
1,6-diisocyanatohexamethylene
EPITOPE ID:115018
gtpl6291
SCHEMBL15038
1,6-diisocyanato hexane
ocn-(ch2)6-nco
hexamethylene di-isocyanate
W-104184
CHEMBL1896533
mfcd00002047
hexamethylene diisocyanate, purum, >=98.0% (gc)
Q418197
1,6-hexamethylene-diisocyanate
PD051392
53895-37-7
EN300-20358

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The combination of autoclave sterilization and a PU produced from a larger-molecular-weight polyol is recommended to minimize the production of potentially toxic compounds."( The relative safety of gamma-ray, autoclave, and ethylene oxide gas sterilization of thermosetting polyurethane.
Shintani, H,
)
0.13
" All studies demonstrated that adverse effects were caused by irritation-related responses occurring predominantly in the lower respiratory tract."( Inhalation toxicity of 1,6-hexamethylene diisocyanate homopolymers (HDI-IC and HDI-BT): results of subacute and subchronic repeated inhalation exposure studies.
Mohr, U; Pauluhn, J, 2001
)
0.62
" When the ratio of functional side chain to bis-GMA is increased, the stereo hindrance of resin structure is increased, more toxic resin monomers are trapped in the complicated resin structure, and thus the resin matrix reveals less cytotoxicity."( Biocompatibility and cytotoxicity of two novel low-shrinkage dental resin matrices.
Jan, YD; Lee, BS; Lin, CP; Tseng, WY, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" Results demonstrated these PU-MIFs hold low water absorption rate and superior biocompatibility, which was highly demanded for maintaining cell viability."( Isolation of viable type I and II methanotrophs using cell-imprinted polyurethane thin films.
Hu, Y; Lu, Y; Ren, X; Xie, L, 2014
)
0.4

Dosage Studied

ExcerptRelevanceReference
" Basal ACH dose-response curves, measured twice in intervals of 1 h using tracheal preparations of 11 guinea pigs previously not exposed to IC, were reproducible."( Subchronic exposure to diisocyanates increases guinea pig tracheal smooth muscle responses to acetylcholine.
Baur, X; Marczynski, B; Marek, W; Mensing, T; Potthast, J, 1999
)
0.3
" The dose-response curve of HDI-induced pulmonary responses in naïve or dermally sensitized rats after one or several inhalation priming exposures was examined in the Brown Norway (BN) rat asthma model."( Analysis of the interrelationship of the pulmonary irritation and elicitation thresholds in rats sensitized with 1,6-hexamethylene diisocyanate (HDI).
Pauluhn, J, 2015
)
0.63
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
haptenAny substance capable of eliciting an immune response only when attached to a large carrier such as a protein. Examples include dinitrophenols; oligosaccharides; peptides; and heavy metals.
allergenA chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
diisocyanateAn isocyanate compound containing two isocyanate functional groups. Manufactured for reaction with polyols in the production of polyurethanes.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.69630.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency67.05790.000714.592883.7951AID1259369
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency23.79310.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency26.69630.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency23.79310.003041.611522,387.1992AID1159552
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.95230.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849
pregnane X nuclear receptorHomo sapiens (human)Potency47.47340.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency1.11610.000229.305416,493.5996AID743075
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency38.03550.057821.109761.2679AID1159526
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency19.95260.010039.53711,122.0200AID588547
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1346556Human TRPA1 (Transient Receptor Potential channels)2009FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Apr, Volume: 23, Issue:4
Transient receptor potential ankyrin 1 antagonists block the noxious effects of toxic industrial isocyanates and tear gases.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (277)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (11.19)18.7374
1990's60 (21.66)18.2507
2000's85 (30.69)29.6817
2010's91 (32.85)24.3611
2020's10 (3.61)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.21 (24.57)
Research Supply Index5.70 (2.92)
Research Growth Index4.75 (4.65)
Search Engine Demand Index36.32 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.67%)5.53%
Reviews8 (2.69%)6.00%
Case Studies15 (5.05%)4.05%
Observational0 (0.00%)0.25%
Other272 (91.58%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]